A.R.T. Advisors LLC increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1,665.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 40,600 shares of the specialty pharmaceutical company’s stock after buying an additional 38,300 shares during the period. A.R.T. Advisors LLC owned about 0.07% of Jazz Pharmaceuticals PLC worth $4,426,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Howard Hughes Medical Institute bought a new position in shares of Jazz Pharmaceuticals PLC during the third quarter valued at about $112,000. Brave Asset Management Inc increased its position in shares of Jazz Pharmaceuticals PLC by 540.0% in the third quarter. Brave Asset Management Inc now owns 960 shares of the specialty pharmaceutical company’s stock valued at $117,000 after buying an additional 810 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 10.7% in the third quarter. Daiwa Securities Group Inc. now owns 1,550 shares of the specialty pharmaceutical company’s stock valued at $188,000 after buying an additional 150 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its position in shares of Jazz Pharmaceuticals PLC by 2.4% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,557 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 37 shares in the last quarter. Finally, World Asset Management Inc increased its position in shares of Jazz Pharmaceuticals PLC by 15.0% in the third quarter. World Asset Management Inc now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $203,000 after buying an additional 217 shares in the last quarter. Hedge funds and other institutional investors own 88.56% of the company’s stock.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 1.07% on Thursday, reaching $136.41. The company’s stock had a trading volume of 543,205 shares. The stock has a market capitalization of $8.17 billion, a PE ratio of 23.86 and a beta of 1.22. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $160.00. The stock has a 50-day moving average of $121.81 and a 200 day moving average of $120.32.

This piece was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this piece can be accessed at http://www.watchlistnews.com/a-r-t-advisors-llc-boosts-stake-in-jazz-pharmaceuticals-plc-jazz/1121326.html.

Several research analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $187.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, January 24th. TheStreet downgraded Jazz Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, November 8th. Guggenheim restated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Thursday. Deutsche Bank AG restated a “buy” rating and set a $148.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, January 19th. Finally, BMO Capital Markets restated an “outperform” rating and set a $192.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, January 12th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $179.92.

In other news, Director Patrick G. Enright sold 677 shares of the stock in a transaction that occurred on Friday, December 2nd. The shares were sold at an average price of $101.80, for a total value of $68,918.60. Following the completion of the transaction, the director now directly owns 1,365 shares in the company, valued at $138,957. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Russell J. Cox sold 4,000 shares of the stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $128.75, for a total transaction of $515,000.00. The disclosure for this sale can be found here. Insiders sold 5,077 shares of company stock valued at $627,723 over the last quarter. Insiders own 3.90% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.